Group-IB Study

Counterfeit products put manufacturers’ brands at risk of their luxury status being diluted and lost, which ultimately leads to buyers losing interest in the brand. Lowquality counterfeit medicines can both harm the health of consumers and negatively affect a brand’s reputation.

Mass migration of sellers of all product types to the online sector takes the issue of ensuring information security to a new level. Cyberthreats and increasingly frequent cases of digital fraud are key challenges in the transition to e-commerce. In the pharmaceutical industry, the distribution of poor-quality products under official brand names can damage not only customer loyalty, but also people’s health.

What can be found in the white paper?

• Examination of the methods used by criminals to abuse pharmaceutical brands and popular drugs
• Assessment of the risk levels for various medicine distribution channels
• Estimation of the volume of counterfeit drugs sold